InvestorsHub Logo
Followers 64
Posts 5557
Boards Moderated 0
Alias Born 01/17/2005

Re: masterlongevity post# 755

Wednesday, 03/10/2010 8:43:40 PM

Wednesday, March 10, 2010 8:43:40 PM

Post# of 890

<" still skeptical about clinical endpoints ">

Its the same for almost every p3 trial program. There was enough evidecne to take it forward to p3, despite in fact a small trial size.

I am just watching the Cowen show, and the stock seems incredinly under-valued.